Harmony Biosciences Holdings, Inc. (HRMY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Plymouth Meeting, PA, United States. The current CEO is Jeffrey Dayno.
HRMY has IPO date of 2020-08-19, 268 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $1.69B.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
